# 5/st GLOBAL CONGRESS ON MIGS

December 1-4, 2022 | Gaylord Rockies Resort and Convention Center | Aurora, Colorado

# SYLLABUS

UROGYN-612: Urogyn for the MIGS Surgeon:
Apical Support

## **Table of Contents**

Financial Disclosures	3
Course Program: Course Description, Learning Objectives, Course Outline	4
Laparoscopically Tackling the Apex: Native Tissue Approach: Uterosacral Colpopexy, Richardson Stitch T. Ferzandi	5
Laparoscopically Tackling the Apex: Mesh Augmented: Sacral Colpopexy J. Mourad	12
The OG Method: Vaginal Surgery: Uterosacral and Sacrospinous Ligament Fixation L.G. Oliveira Brito	16
Hysteropexy: Vaginal Uterine Conservation Technique L. Siff	21
Laparoscopic Uterine Conservation S. Fatehchehr	26
vNOTES: Combining the Best of MIS A. Park	30
Cultural and Linguistic Competency & Implicit Bias	33

#### **Disclosure of Relevant Financial Relationships**

As an ACCME accredited provider, AAGL must ensure balance, independence, and objectivity in all CME activities to promote improvements in health care and not proprietary interests of an ineligible company. AAGL controls all decisions related to identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons in a position to control content, selection of educational methods, and evaluation of the activity. Course chairs, planning committee members, faculty, authors, moderators, and others in a position to control the content of this activity are required to disclose all financial relationships with ineligible companies. All relevant financial relationships are appropriately mitigated, and peer review is completed by reviewers who have nothing to disclose. Learners can assess the potential for commercial bias when disclosure, mitigation of conflicts of interest, and acknowledgment of commercial support are provided prior to the activity. Informed learners are the final safeguards in assuring that a CME activity is independent from commercial bias. We believe this mechanism contributes to the transparency and accountability of CME.

Asterisk (\*) denotes no financial relationships to disclose.

#### **PLANNER DISCLOSURE**

The following members of AAGL have been involved in the educational planning and/or review of this course (listed in alphabetical order by last name).

Linda D. Bradlov, MD. Modical Director, AAGL\*

Linda D. Bradley, MD, Medical Director, AAGL\*

Erin T. Carey, MD, MSCR Honorarium: Med IQ Research Funding: Eximis Mark W. Dassel, MD\*

Linda Michels, Executive Director, AAGL\*

Vadim Morozov, MD Speaker: AbbVie

Consultant: Medtronic, Lumenis

Erinn M. Myers, MD

Speakers Bureau: Intuitive Surgical

Amy J. Park, MD Speaker: Allergan

Nancy Williams, COO, CME Consultants\*

Harold Y. Wu, MD\*

Sven Becker, MD, PhD – Speaker's Fees: Olympus, Storz, Medtronic, Hologic, Gedeon-Richter, Roche, MSD, Bayer, GSK, Pharmamar, GE, Philips, Intuitive, Merck,

Lily, Pierre-Fabre, Jenapharm, Zeiss

Giovanni Scambia, MD – Speakers Bureau: Intuitive Surgical; Baxter; Olympus; GlaxoSmithKline; Consultant:

Medtronic; AstraZeneca; Johnson & Johnson

#### **SCIENTIFIC PROGRAM COMMITTEE**

Andrew I. Sokol, MD - Medical Legal Defense: Johnson & Johnson

Angela Chaudhari, MD - Consultant: Johnson & Johnson

Cara R. King, DO\*

Mario Malzoni, MD – Consultant: KARL STORZ Jessica Opoku-Anane, MD, MS – Consultant: Boston

Scientific; Myovant Sciences; AbbVie Shailesh P. Puntambekar, MD, PHD\*

Frank F. Tu, MD, MPH\*

Jonathon M. Solnik, MD – Consultant: Olympus; Medtronic;

Stockholder: Field Trip Health, Inc.; Felix Health Linda D. Bradley, MD, Medical Director\* Linda Michels, Executive Director, AAGL\*

#### **FACULTY DISCLOSURE**

The following have agreed to provide verbal disclosure of their relationships prior to their presentations. They have also agreed to support their presentations and clinical recommendations with the "best available evidence" from medical literature (in alphabetical order by last name).

Luiz Gustavo Oliveira Brito, MD – Consultant: Promedon; Astellas; AstraZeneca; Speakers Bureau - Promedon; Astellas; AstraZeneca; Board: AAGL, IUGA, SoMe Editor –

Soorena Fatehchehr, MD, MSc\*

Tanaz Ferzandi, MD – Advisory Board: Coloplast

Jamal Mourad, DO\*

Amy Park, MD – UptoDate: Royalties; Speaker: Allergan

Lauren Siff, MD\*

#### **URO-612: Urogyn for the MIGS Surgeon: Apical Support**

Co-Chairs: Tanaz Ferzandi, MD, Luiz Gustavo Oliveira Brito, MD

Faculty: Soorena Fatehchehr, MD, MSc, Jamal Mourad, DO, Amy Park, MD, Lauren Siff, MD

#### **Course Description**

This course is designed for the MIGS surgeon to address the vaginal apex, the cornerstone of vaginal support. It is important to understand the functionality of correcting the apex as this correlates with other defects, such as the anterior compartment. We will provide data regarding the best approach for surgical restoration of the anatomy in a long-term fashion, and the recent growing of uterine preservation.

#### **Learning Objectives**

At the conclusion of this course, the participants will be able to: 1) Diagnose POP (Baden Walker vs. POPQ) and consider different possible surgical approaches; 2) Describe different approaches for sacrocolpopexy, uterosacral ligament suspension and 3) Follow the indications for hysteropexy and the recent data comparing with standard, vaginal hysterectomy for apical prolapse.

#### **Course Outline**


9:45 am	Welcome, Introduction and Course Overview	T. Ferzandi/L.G. Oliviera Brito
9:50 am	Laparoscopically Tackling the Apex: Native Tissue Approach: Uterosacral Colpopexy, Richardson Stitch	T. Ferzandi
10:10 am	Laparoscopically Tackling the Apex: Mesh Augmented: Sacral Colpopexy	J. Mourad
10:30 am	The OG Method: Vaginal Surgery: Uterosacral and	L.G. Oliveira Brito
	Sacrospinous Ligament Fixation	Liei envena zinte
10:50 am	Hysteropexy: Vaginal Uterine Conservation Technique	L. Siff
11:10 am	Laparoscopic Uterine Conservation	S. Fatehchetr
11:30 am	vNOTES: Combining the Best of MIS	A. Park
11:50 am	Questions & Answers	All Faculty
12:15 pm	Adjourn	


# **Apical Support**


Urogynecology for the MIG Surgeon
51<sup>st</sup> AAGL Global Congress on Minimally Invasive Gynecologic Surgery
December 1, 2022
Aurora, CO

#### Disclosures related to this talk

• Advisory Board - Coloplast







Apical
(Robot Assisted, Laparoscopy, Abdominal, Vaginal)

Sacrocolpopexy (post hysterectomy)
SCH with Sacrocervicopexy
Gacrohysteropexy
Uterosacral ligament suspension (uterus or vault)
Sacrospinous fixation, +/- vaginal hysterectomy
Sacrospinous Hysteropexy
Iliococcygeal Vaginal Suspension
[[Rectopexy]]


- Anterior Compartment +/- Graft or Mesh

  - Anterior ColporrhaphyParavaginal Defect Repair (vaginal, abdominal)
- Posterior Compartment +/- Graft or Mesh
  - Posterior Colporrhaphy levator plication
  - Posterior Colporrhaphy site specific
     Sacrospinous Ligament Fixation
- Obliterative (with uterus or post-hysterectomy)
  - Le Fort Colpocleisis (or "colpectomy")

#### Sacrocolpopexy (SCxP)

- First described in 1962, Dr. Frederick Lane
- Grade A: SCxP preferred for vaginal apical prolapse
- Grade B: monofilament polypropylene mesh preferred graft
- Grade B: LSC is preferred technique
- Grade C: either permanent or delayed abs sutures @ vagina
- Grade C: permanent sutures or tackers @ sacral promontory
- Grade C: closing peritoneum over mesh
- Insuff evidence/conflicting data on total vs. SCH
- Insuff evidence/conflicting data for uterine preservation
  - Nevertheless, uterus preservation is associated with less mesh erosion (Grade B)






#### Steps

- After hysterectomy
  - Anterior dissection cvx/vaginal vault
     Back fill bladder delineate borders

    - Monopolar cautery to dissect · Caution with detrusor mm
      - Caution with over-correction anterior
  - Posterior Dissection
    - EA Sizer in rectum if there has been prior surgery / scarring
       Avoid very distal dissection to the perineal body



#### Steps - cont'd

- Type of mesh
  - Type 1, polypropylene
  - Y-shaped vs. create own mesh
- Goretex vs. Delayed Abs sutures (vs. barbed)
  - How many is ideal?
  - Intracorporeal vs Extracorporeal knot tying
- Placement through ligament
  - NOT sacral promontory
- Re-peritonealization of mesh
  - Technique
  - $\ ^{\centerdot}$  ? Risk of bowel obstruction with barbed suture

#### Delayed Complication: Lumbar spondylodiscitis





#### Lumbar spondylodiscitis

- 36.5% laparotomy
- 44.2% laparoscopic in 44.2%
- 15.4% robotic-assisted
- 63.5% cases Sacral anchorage was performed with synthetic mesh (nonabsorbable or partially absorbable)
- Biologic mesh 1.9%, direct sutures 3.8%
  - 25% of all cases, the type of sacral anchorage was not specified.
- The attachment to the promontory
  - was made with sutures in 36.5% (all nonabsorbable sutures)
  - staples, clips, tacks or screws in 23% of the cases
    Information lacking in 40.4% of the cases

#### Where to tack the mesh?

- Review of 21 cases of pyogenic spondylitis
- Authors determined that the safest site of securing the mesh was the "true" sacral promontory which lies 1.5 cm below L5-S1 intervertebral





Do we need to perform systematic supracervical hysterectomy during laparoscopic Sacrocolpopexy?

- Ninety, four patients were included in the study.
- 64 patients (68.1%) received promonto fixation with subtotal hysterectomy, 12 patients (12.7%) received uterine-sparing promonto fixitis, 16 patients (17%) had a history of hysterectomy, and 2 patients (2.2%) received promonto fixation with total hysterectomy.
- The mean age of patients was  $61\pm20$  years, parity was  $2\pm2$  and body mass index was  $25.2\pm7.32$ . The objective success rate, defined as a < 2 POP-Q stage, was 93.75% in the promonto fixation with subtotal hysterectomy group vs. 66.7% in the uterine-preserved promonto fixation group (p=0.019).


   The subjective success rates were 98.4% and 83% respectively (p = 0.063 ns).
- Conclusion
- Promonto fixation offers good anatomical results, with better objective and subjective success rates when combined with subtotal hysterectomy.


#### LSC SCH vs LSC total hyst – national trends

- 2010 2017
- 7729 surgical cases: 4292 (55.0%) total hysterectomy and 3480 (45.0%) supracervical hysterectomy
- 2014 FDA safety communication re: power morcellation
- Concurrent total hysterectomy remained relatively unchanged from 64.2% in 2010 to 52.5% in 2017
- No significant change in trend between 2010 2017
  - · LOS greater for SCH group (2d)

#### Danger Danger ...

- Median sacral artery
- Left common iliac vein
- Aortic bifurcation
- · Right ureter
- L5-S1 disc space





#### Managing brisk intra-operative bleeds

- Prevention
- Management
- Basic Hemostatic Techniques
- Laparoscopic Hemostasis
- Management of bleeding at the sacrum

#### **Preoperative Preparedness**

- Recognition of procedures at high risk for heavy bleeding
- Appropriate preoperative laboratory evaluation
- · Crossmatched blood available
- OR team informed of likelihood that bleeding may be encountered
  - Plan reviewed
  - Tools available

#### Management

- Alert the OR team
  - Ask for the help you need
- Anticipate Resuscitation
  - · Alert anesthesia
  - Call for blood
- Get visualization • Suction, packs, extra hands
- Communication
- "Slow is smooth, and smooth is fast"
- TTT! (Dr. Magrico)

#### Basics of Hemostasis


- APPLY PRESSURE

  - Laparotomy
     Finger
     Sponge stick
     Damp laparotomy pads
- Identify and control localized bleeding
  - Visualization
  - · Ligate or cauterize as appropriate
  - Use of hemostatic agents for low-volume bleeding
- Get Help

  - Vascular surgery
     Interventional radiology

#### Laparoscopic Hemostasis Techniques

- Visualization
  - · Suction irrigator
  - · Increase insufflation pressure and flow settings
- Apply Pressure
  - Atraumatic grasper to bleeding site
  - 4 x 8 gauze sponges to hold pressure
  - Increase insufflation pressure for small bleeds
  - · Convert to laparotomy



#### Take Home Points

- Prepare
- Communicate
- APPLY PRESSURE
- Maintain control
- Ask for help
- Keep learning!

### Sacrospinous Ligament Fixation (SSLF)

#### SSLF


- Transvaginal surgical treatment is mainly represented by the sacrospinous ligament fixation
- Sederl 1958; Richter 1968; Randall and Nichols 1971
- Sutures the posterior vaginal wall to the sacrospinous ligament
- Compared to sacrocolpopexy, SSLF


  - avoid abdomen
     higher rate of dyspareunia
     higher recurrence
     lower morbidity
     shorter intervention time
     faster postoperative recovery


# Basic Steps:

- Exposure (Ione star!)
- Infiltration
- Vaginal incision
- Recto-vaginal dissection
- Pararectal dissection
- SSL suture
- Vaginal fixation (with vaginal strips)
- Vaginal closure
- SSF
- Final closure.










#### USLS vs. SSF

- The recurrence rates in literature varies widely, 0 to 70.3% in the OPTIMAL trial
- OPTIMAL trial, randomized, compared uterosacral ligament suspension versus SLF
  - the recurrence rates were respectively 61.5% and 70% without any significant

#### Vaginal axis after abdominal sacrocolpopexy versus vaginal sacrospinous fixation—a randomized trial



#### Adverse Events:

- Gluteal pain requiring removal of stitch(es)
- Bleeding
- Injury to rectum (ureter, bladder)
- Constipation
- UTI
- Dyspareunia
- Myositis
- Perineal necrotizing infection of the gluteal region

#### Uterine preservation or not? SSF Hysteropexy

- recurrence rate was 19.5%
- retreatment rate was 11.0%

  - to extinctle was the most common recurrent compartment (17.1%)

     the uterine preservation group (n=66) was younger, had lower parity, and had fewer stage 3 to 4 cystoceles and uterine prolapses than the concomitant hysterectomy group (n=16)

     Shorter operation times (99.4 minutes vs 153.7 minutes, P=.002) and lower anatomical recurrence rates (11.5% vs 45.5%, P=.039) were found in the uterine preservation group before and after PSM
  - Previous pelvic organ prolapse surgery (hazard ratio 3.14) and concomitant hysterectomy (hazard ratio 4.08) were identified as risk factors for anatomical recurrence
  - most common adverse event was buttock pain (14.6%) resolved spontaneously within 4 weeks
- compared with concomitant hysterectomy, SSLF with uterine preservation reduces the anatomical recurrence rate.

#### Uterine preservation or not? SSF v USLS


- 4 sites, 147 patients underwent SSHP and 114 underwent USHP • SSHP patients were younger, higher BMI
- One year postop: 1 in 3 patients were available for follow-up
  - on odifferences in prolapse recurrence between patients who underwent USHP versus SSHP
  - adverse events was low and less than 5% of patients underwent subsequent hysterectomy for prolapse


ooburn, K.L., Yuan, A, Torosis, M., Roberts, K., Ferrando, C. and Galman, R.E., 2022. Sacrospinous flasion and vaginal ularosacrali suspension: evaluation in ularine preservation surpery. Americae Journal of Chistehica & Gyvecology, 22(3), p.51273

CYSTOSCOPY after all these procedures

#### World Health Organization

"health is a state of complete physical, mental, and social well-being, not merely the absence of disease or infirmity"





#### Objectives


- Discuss the role of the MIGS surgeon in the treatment of POP?
- Review the surgical approach to a RSCP with mesh
- Summarize possible complications associated with SCP.
































### Sacocolpopexy

**Graft Options** 

Natural graft: fascia lata, rectus fascia, dura mater

Autologous: fascia lata, rectus fascia Allogenic: fascial lata, dermal grafts

Synthetic grafts: polypropylene, polyester fiber, polytetrafluoroethylene, Dacron

Type 1 mesh (polypropelene) standard of care **≱**|**A** 

Banner University Medicine



#### SCP – Postoperative Complications

- Mesh exposure 1-10%
  - Higher mesh erosion rate from older mesh types
  - Supracervical hyst decreases mesh exposure rate
- Cystotomy
- Small bowel obstruction (higher in Abdominal vs Laparoscopic)
- · Sacral osteomyelitis





#### Apical - Sacrocolpopexy vs Vaginal Vault suspension

- No direct comparison between SCP vs vaginal repairs
- Meta-analysis 2016 (Cochrane)
  - · POP Symptoms more common after vaginal repairs (7% vs 14%)
  - Repeat Surgery more common after vaginal repairs (4% vs 8%)
  - · Recurrent prolapse more common after vaginal repairs (22% vs 41%)
  - Dyspareunia more common after vaginal repairs
- Ileus and SBO more common in abdominal group (2.7% vs 0.2%)
- VTE higher in abdominal group (0.6% vs 0.1%)
- Mesh complications present with SCP (1-2%)



Banner University Medicine




#### HOLD FOR VIDEO


- Wu JM, Matthews CA, Conover MM, Pate V, Jonsson Funk M. Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol 2014;123:1201–6.
- 2. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminol- ogy for female pelvic floor dysfunction. International Urogynecological Association, International Continence Society. Neurourol Urodyn 2010;29:4–20.
- Swift S, Woodman P, O'Boyle A, Kahn M, Valley M, Bland D, et al. Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol 2005;192:795–806.
- 4. Cundiff GW, Amundsen CL, Bent AE, Coates KW, Schaffer JI, Strohbehn K, et al. The PESSRI study: symptom relief outcomes of a randomized crossover trial of the ring and Gellhorn pessaries. Am J Obstet Gynecol 2007;196:405.e1–8.
  5. Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JO, Klarskov P, et al. The standardization of terminology of female pelvic organ prolapse and pelvie floor dysfunc- tion. Am J Obstet Gynecol 1996;175:10–7.
- 6. Hall AF, Theofrastous JP, Cundiff GW, Harris RL, Hamilton LF, Swift SE, et al. Interobserver and intraob-server reliability of the proposed International Continence Society, Society of Gynecologic Surgeons, and American Urogynecologic Society pelvic organ prolapse classifica-tion system. Am J Obstet Gynecol 1996;175:1467–70; discussion 1470–1.
- WH, Rosenberger K, Walters MD. Interobserver variation in the assessment of pelvic organ prolapse. Int










































































#### Disclosures

I have no financial relationships to disclose





#### Objectives

- Discuss Indications and Contraindications to Uterine Conservation
- Discuss the transvaginal options for hysteropexy to treat POP and their comparative effectiveness/ perioperative outcomes
- Review the surgical approach to transvaginal hysteropexy
- Summarize possible complications associated with hysteropexy





#### Indications for Uterine Conservation

- •Cross-sectional studies have shown 36–60% of women with symptomatic prolapse would decline hysterectomy for prolapse repair if given an equally efficacious uterine
- preserving technique.
  •Denmark: 2010-2016 Huge shift from TVH to Uterine sparing procedures: if high level specialty 90% became uterine conserving, if moderately specialized 40% Hysteropexy
- Reasons for preserving uterus
  - · desire for future fertility
  - belief that the uterus may affect sexual function

  - Uterus relates to sense of identity
     Desire to avoid surgical risks of hysterectomy itself (decreased op time, ebl etc)
- •Uterus is an innocent bystander in prolapse and may not be necessary to apical pport




#### Contraindications for Uterine Conservation

•Cancer risk (uterine, ovarian, or cervical) atient lifetime risk of co

rical (0.6%), uterine (2.7%), and ovarian (1.4%) and need for continued screening \*Lynch syndrome and BRCA 1 or 2. personal history of ER+ breast cancer consider hyst with

Obesity (relative contraindication)

- PMB: even with negative workup given 13% risk of unanticipated endometrial cancer or despite
- Cervical elongation (relative contraindication)
  - Up to 11 Fold increase in failure w sshp for cervical elongation
     Partial trachelectomy has improved this success rates up to 96–99%







Pros and Cons to Uterine Conservation				
Advantages	Disadvantages			
Reduction surgical time	Fewer surgical outcome data			
Reduction in blood loss	Maintenance of fertility			
Maintain fertility	Risk for malignancy (uterine, cervical)			
Allows for natural menopause	Continuation of menses			
Sexual satisfaction	Need for surveillance of cervix and endometrium			
Less invasive procedure	Inability or difficulty accessing cervix or endometrium for surveillance			
Faster recovery	Less surgeon experience with			
Decreased risk mesh exposure similar prolapse outcomes Patient preference	prolapse repair and hysteropexy			

#### Surgical Options for Transvaginal Hysteropexy

- •Sacrospinous Hysteropexy
- •Uterosacral Hysteropexy
- •Lefort Colpocleisis
- Manchester Procedure
- •Transvaginal Mesh Hysteropexy





#### Sacrospinous Hysteropexy

- •SSHP is EXTRAPERITONEAL= advantages in pelvic adhesive disease
- Like SSLF, deflects the vagina posteriorly, which may contribute to anterior vaginal wall prolapse recurrence (despite AR).
- ${}^{\bullet}\text{Comparable}$  apical success for SSHP v TVH/USLS, shorter hospitalization, quicker return to work



Bradley Cur Uro Reports 2018

# Anatomic Landmark Review Sciatic N. Pudenda /a/n SSI. Ischial Spine

#### Complications of SSLF

- Vascular- Massive inaccessible hemorrhage
- Neurologic- BUTTOCK PAIN!!





#### SSL Hysteropexy Posterior Video

- Transvaginal sacrospinous hysteropexy | SpringerLink (vcu.edu)
- Posterior approach





#### SSL Hysteropexy Anterior Approach Video

- Native tissue sacrospinous hysteropexy from an anterior approach | SpringerLink (vcu.edu) Matthews
- Petruzzelli
- https://youtu.be/QdgVw4YkJWI 3 min video





#### Uterosacral Ligament Hysteropexy

- •Laparoscopic, Vaginal or Abdominal Approach
- •Large retrospective cohort found no difference in outcomes for apical success (<stage 2) for VUSH (n = 100) and TVH/USLS (n = 100), (96 vs 97%, p = 0.90)
- •No difference in anterior or posterior compartment objective outcomes at 24 months

 ${}^\bullet \! No$  RCTs and some conflicting data with other approaches when comparing to TVH/USLS

Romanzi IUJ 2



#### USLS Hysteropexy video

• 10.1007/s00192-016-3222-2





#### Vaginal Mesh Hysteropexy



- •Mesh graft on Anterior Wall and SSL.
- •Cochrane review shows level 1 evidence for improved success rates for anterior vaginal wall support with mesh vs without
- •Initially 40 vaginal mesh products on the market, Now uphold, self cut or none
- •AUGS ACOG and SUFU published guidelines for use and states these procedures can be safe and effective when selecting the right surgical candidate.
- PFDN (SUPER Trial): (Uphold™) mesh hysteropexy to TVH/ USLS repair n=180, pop failure rates of 37% vs 54%. Mesh exposure (8% vs 0%), granulation tissue after 12 weeks (1% vs 12%), and suture exposure after 12 weeks (3% vs 21%)
- Vaginal mesh hp vs Ishp no difference in 1 yr cure, high satisfaction mesh exposure 3% Ishp and 7% vaginal mesh




#### The Manchester procedure

- •1888 by Dr. Archibald Donald in Manchester England
- •Trachelectomy + plication of the cardinal and uterosacral ligaments in the midline •primarily used for cervical elongation in an era where no antibiotic prophylaxis
- existed, and rates of postoperative infection were high with total hysterectomy.
- But now has had a resurgence with increased desire for hysteropexy, The Danish study with shift to uterine sparing 75% Manchester 25% SSHP
- ullet MP vs. TVH showed shorter operative times and lower estimated blood loss, no difference in hospital stay, no difference in apical support , no difference in sexual function







#### Manchester Procedure

- https://static-content-springercom.proxy.library.vcu.edu/esm/art%3A10.1007%2Fs00192-017-3284-9/MediaObjects/192 2017 3284 MOESM1 ESM.mp4
- IMBED VIDEO HERE





#### Obliterative Repair: Lefort Colpocleisis

- Frail, Elderly, Medically Complex, Advanced Prolapse, Does not desire future vaginal intercourse
- High Satisfaction >90%
- Low complication Rate
- · Improved body Image, low regret
- shorter operative time, lower blood loss, and similar anatomic success with LeFort vs TVH w total coloocleisis







#### Risks for Recurrences

- TVH/USLS vs SSHP: BMI, smoking POPQ Ba at 5 years post treatment (composite outcomes of anatomy beyond hymen, bothersome bulge, repeat surgery or pessary)
- TVH was a risk factor for posterior compartment recurrence when compared with sacrospinous hysteropexy (93 events in 40 women; odds ratio, 5.21; 95% confidence interval, 2.05-13.27; P<.01).



Schulten AJOG 2022



#### Comparative Effectiveness between options

- · There are no RCTs comparing hysteropexy procedures to date RETROSPECTIVE DATA:
- SSHP vs MP vs TVH: The 5-year reoperation rates were 30%, 7% and 11%(Husby IUJ 2019)
   BIT Metanalysis of SSHP vs thrusls not different
   USH vs TVH USLS similar cure
- · SSHP vs. TVH USLS similar cure
- Stage 4 POP higher recurrence with SSHP

  The largest retrospective study: 240 HP: vaginal mesh (n = 61), LSHP (n = 43), RASHP (n = 27), ASHP (n = 15), and native tissue VHP (n = 99). POP recurrence (>stage 1 and bulge symptoms) 12% not different between
- groups

  \*No differences in vaginal native tissue vs vaginal mesh (12 vs 10%, p = 0.71) or laparoscopic non-mesh versus mesh repairs (10 vs 23%, p = 0.07). Mesh exposure similar vag. Vs. Is (2 vs. 2.4%)

  \*Only prospective study comparing two HP: LSHP vs Vaginal Mesh HP: same cure, vaginal mesh exposure specified ry% vs. 3%



#### **Future Fertility**

- Case series: 8 women prior SSHP conception 16 months after pop surgery, Delivered by C/s, only 1/8 preterm (due to twins), 87.5% (7/8) were satisfied w POP outcomes and sexual function at F/u (median 45months postpartum)
- Manchester has a higher risk of miscarriage and preterm birth.
- If desire future fertility, prefer no mesh, and USH or SSHP
- Limited data regarding the route of delivery in those with a prior hysteropexy, there are no recommendations that C/S is protective but most do



#### TAKE HOMES

- Vaginal native tissue uterine conservation POP surgery is safe and effective can be as effective as TVH/USLS
- ·Great for those desiring future fertility, or personal preference for identity or decreased operative risk
- •Not for people with high risk for cancer (genetic, obesity, or PMB)
- •Consider alternatives for cervical elongation, Stage 4 pop or Advanced
- Sexual function is improved in all and not different between procedures
- Fertility is possible and likely delivery via C/S

an consider Mesh in right candidate with right counseling



#### References

in women with decrossignal produces Syster results or a randomeror some line(5) spg.2001.030 Hz. (E. et al. Efficie of Viginal Model Hysterrocks v. V. Viginal Hysterrockery, With Unconserved Ligarnett Suspension on Treatment Failure in 10 of CV. Vices AG, Exches Hz. et al. Efficie of Viginal Model Hysterrock v. Viginal Hysterrockery, With Unconserved Ligarnett Suspension on Treatment Failure in With Unconservation Produces: A Bandomirot Clinical Trial ASMA 2019-232(1) 11054. doi:10.1001/jama.2019.128[2].

10.016/j.jap.2022.04.017

10.016/j.jap.2022.04.07

10.016/j.jap.2022.04


10.016/j.j















# Objectives Indications Comparing recent data with standard



# Advantages (1.2) Operating time Blood loss Low complication rates Similar success Excellent patient's satisfaction and quality of life Safe

# Laparoscopic Hysteropexy Laparoscopic Sacrospious hysteropexy Laparoscopic Uterosacral hysteropexy Laparoscopic Sacrohysteropexy Other

# Laparoscopic hysteropexy: 10 years experience (3)

- All hysteropexy 2006-2016
- 507 women
- Complications were rare (1.8%) with no evidence mesh exposure
- Mean operating time 62.5 min and median length of stay 2 nights

# Laparoscopic hysteropexy: 10 years experience (9)

- In 17 patients (3.4%), hysteropexy was abandoned
- There was a mean change in point C of 7.9 cm
- 93.8% felt their prolapse was "very much" or "much" better. 2.8% had repeat apical surgery

# Clinical outcomes in women undergoing laparoscopic hysteropexy: A systematic review (4)

- 770 patients in 17 studies received the intervention being studied (laparoscopic hysteropexy) with success rates of 85.32% (95%CI: ±2.5)
- Laparoscopic suture hysteropexy success of 70.5% (95%CI:±5.33) VS 92% (95%CI:±2.53) suspension to the sacral promontory using mesh or tape
- One small study on suspension to the anterior abdominal wall (28 cases) and one to the pectineal ligament (18 cases) have shown 96.4% (95%CI:±6.9) and 94.5% (95%CI:±10.53) objective success rates respectively

# Comparison between laparoscopic sacrocolpopexy with hysterectomy and hysteropexy in advanced urogenital prolapse $_{(5)}$

- · Single site
- Between 2012 and 2016, a total of 136 patients with POP were included (82 LSC with hysterectomy & 54 hysteropexy)
- Median follow-up 65.3 months (36-84 months)
- Improvements in the anatomical and functional outcomes of both groups without differences between the two approaches.
- The apical success rate was 100% in all women, without recurrence in either group; the anterior and posterior success rates of hysterectomy were higher than those of uterine preservation.

### Vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study (6)

- 74 laparoscopic sacral hysteropexy and 76 vaginal mesh hysteropexy procedures from July 2011 through May 2014
- Laparoscopic patients were younger (P < .001), had lower parity (P = .006), were more likely premenopausal (P = .008), and had more severe prolapse (P = .02)</li>
- Laparoscopic procedure (174 vs 64 minutes, P < .0001) and total operating time (239 vs 112 minutes, P < .0001) were longer
- There were no differences in blood loss, complications, and hospital stay

## Vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study $_{\rm (6)}$

- One-year outcomes: 83% laparoscopic and 80% vaginal hysteropexy
- No differences in anatomic (77% vs 80%; OR, 0.48; P = .20), symptomatic (90% vs 95%; OR, 0.40; P = .22), or composite (72% vs 74%; OR, 0.58; P = .27) cure
- Mesh exposures 2.7% laparoscopic vs 6.6% vaginal hysteropexy (P = .44)
- A total of 95% of each group were very much better or much better. Pelvic floor symptom and sexual function scores improved for both groups with no difference between groups
- •

Hysteropexy in the treatment of uterine prolapse stage 2 or higher: laparoscopic sacrohysteropexy versus sacrospinous hysteropexy-a multicenter randomized controlled trial (LAVA trial)  $_{(7)}$ 

- Multicenter randomized controlled, non-blinded non-inferiority trial
- 126 women with uterine prolapse stage 2 or higher undergoing surgery without previous pelvic floor surgery
- Laparoscopic sacrohysteropexy was non-inferior for surgical failure (n = 1, 1.6%) compared with SSHP (n = 2, 3.3%, difference -1.7%, 95% CI: -7.1 to 3.7) 12 months postoperatively

Hysteropexy in the treatment of uterine prolapse stage 2 or higher: laparoscopic sacrohysteropexy versus sacrospinous hysteropexy-a multicenter randomized controlled trial (LAVA trial)  $_{(7)}$ 

- No anatomical recurrences and quality of life difference
- More bothersome symptoms of overactive bladder (OAB) and fecal incontinence were reported after LSH
- Dyspareunia was more frequently reported after SSHP

# Pregnancy following laparoscopic hysteropexy-a case series (8)

- All patients had successful pregnancy outcomes with birth weights on or above the 10th centile
- There was no effect on mesh integrity seen in any of the cases
- There was no deterioration in apical prolapse when assessed post delivery, two patients had new onset anterior vaginal wall prolapse.

# Spotlight On: Urogynecology SIG New Scope

 Sacrohysteropexy with Anterior and Posterior Attachment. Andre Plair,MDCatherine A Matthews,MD, <a href="https://bit.ly/3pv0EaU">https://bit.ly/3pv0EaU</a>

#### Videos

- Failed Mesh Sacral Colpopexy Resulting in Recurrent Uterine Prolapse Treated Successfully with Laparoscopic Sacral Colpohysteropexy, John R Miklos,MDRobert D Moore,DOOrawee Chinthakanan,MD https://bit.ly/3R7fPTK
- Laparoscopic Sacrospinous Ligament Hysteropexy, Samantha Haikal, DORayan A Elkattah, MD <a href="https://bit.ly/3CBdplX">https://bit.ly/3CBdplX</a>
- Cerclage Sacrohysteropexy, Peter L Rosenblatt,MD, https://bit.ly/3CENLmr

#### References

- Laparoscopic sacral hysteropexy versus laparoscopic sacrocolpopexy with hysterectomy for pelvic organ prolapse. Int Urogynecol J2016 Jan;27(1):93-101. doi: 10.1007/s00192-015-2775-9. Epub 2015 Jul 16
- Vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study. Am J Obstet Gynecol . 2017 Jan;216(1):38.e1-38.e11.doi: 10.1016/j.ajog.2016.08.035. Epub 2016 Sep 3
- Laparoscopic hysteropexy: 10 years experience Int Urogynecol J. 2017 Aug;28(8):1241-1248. doi: 10.1007/s00192-016-3257-4. Epub 2017 Jan 18
- Clinical outcomes in women undergoing laparoscopic hysteropexy: A systematic review Eur J Obstet Gynecol Reprod Biol. 2017 Jan;208:71-80
- Comparison between laparoscopic sacrocolpopexy with hysterectomy and hysteropexy in advanced urogenital prolapse Int Urogynecol J 2020 Oct;31(10):2069-2074. doi: 10.1007/s00192-020-04260-1. Epub 2020 Mar 5
- Vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study Am J Obstet Gynecol. 2017 Jan;216(1):38.e1-38.e11.
- Hysteropeey in the treatment of uterine prolapse stage 2 or higher: laparoscopic sacrohysteropeey versus sacrospinous hysteropeay-a multicentre randomised controlled trial (LAVA trial). 2020 Sep;127(10):1284-1293. doi: 10.1111/1471-0528.16242. Epub 2020 May 10
- Pregnancy following laparoscopic hysteropexy-a case series. Gynecol Surg. 2017;14(1):16. doi: 10.1186/s10397-017-1017-1. Epub 2017 Aug 17.







#### Disclosures


UptoDate: royalties Allergan: speaker


### Objectives

- To review indications for vNOTES
- To review vNOTES techniques


### Why vNOTES?


- · Declining hysterectomy rates
- Extol advantages of TVH
- Consider vNOTES as an enabling technology








# Advantages of TVH • Lowest Perioperative morbidity • Lowest resource use...when performed by high-volume vaginal surgeons. Rogo-Gupta, LJ et a1 Obstetrics & Gynecology-December 2010











#### vNOTES expands the minimally invasive surgical repertoire

- Salpingectomies, adnexal surgeries
- vaginal laparoscopic entry into peritoneal cavity in the difficult surgical abdomen
- vaginal morcellation of large uteri after TLH
- drainage of pelvic abscess vaginally



#### References

- Jelovsek JE, Walters MD. Establishing cutoff scores on assessments of surgical skills to determine surgical competence. Am J obstet Gynecol 2010; 203:81
  Burkett D, Horwitz J, Kennedy V et al. Assessing current trends in resident hysterectomy training. Fem Pel Med Reconst Surg 2011; 17: 210
  Antosh D, Gutman R, iglesia CB, Sokol A, Park A. Resident opinions on vaginal hysterectomy training Fem Pel Med Reconstr Surg 2011;17: 314-317
  Guntupalli S et al. Preparedness of ObGyn residents for fellowshp. Obstet Gynecol 2015; (3): 126



#### CULTURAL AND LINGUISTIC COMPETENCY & IMPLICIT BIAS

The California Medical Association (CMA) announced new standards for Cultural Linguistic Competency and Implicit Bias in CME. The goal of the standards is to support the role of accredited CME in advancing diversity, health equity, and inclusion in healthcare. These standards are relevant to ACCME-accredited, CMA-accredited, and jointly accredited providers located in California. <u>AAGL is ACCME-accredited and headquartered in California</u>.

CMA developed the standards in response to California legislation (<u>Business and Professions (B&P) Code Section 2190.1</u>), which directs CMA to draft a set of standards for the inclusion of cultural and linguistic competency (CLC) and implicit bias (IB) in accredited CME.

The standards are intended to support CME providers in meeting the expectations of the legislation. CME provider organizations physically located in California and accredited by CMA CME or ACCME, as well as jointly accredited providers whose target audience includes physicians, are expected to meet these expectations beginning January 1, 2022. AAGL has been proactively adopting processes that meet and often exceed the required expectations of the legislation.

CMA CME offers a variety of resources and tools to help providers meet the standards and successfully incorporate CLC & IB into their CME activities, including FAQ, definitions, a planning worksheet, and best practices. These resources are available on the <u>CLC and IB standards page</u> on the CMA website.

#### **Important Definitions:**

**Cultural and Linguistic Competency (CLC)** – The ability and readiness of health care providers and organizations to humbly and respectfully demonstrate, effectively communicate, and tailor delivery of care to patients with diverse values, beliefs, identities and behaviors, in order to meet social, cultural and linguistic needs as they relate to patient health.

**Implicit Bias (IB)** – The attitudes, stereotypes and feelings, either positive or negative, that affect our understanding, actions and decisions without conscious knowledge or control. Implicit bias is a universal phenomenon. When negative, implicit bias often contributes to unequal treatment and disparities in diagnosis, treatment decisions, levels of care and health care outcomes of people based on race, ethnicity, gender identity, sexual orientation, age, disability and other characteristics.

**Diversity** – Having many different forms, types or ideas; showing variety. Demographic diversity can mean a group composed of people of different genders, races/ethnicities, cultures, religions, physical abilities, sexual orientations or preferences, ages, etc.

#### Direct links to AB1195 (CLC), AB241 (IB), and the B&P Code 2190.1:

Bill Text – AB-1195 Continuing education: cultural and linguistic competency.

Bill Text – AB-241 Implicit bias: continuing education: requirements.

Business and Professions (B&P) Code Section 2190.1

#### **CLC & IB Online Resources:**

Diversity-Wheel-as-used-at-Johns-Hopkins-University-12.png (850×839) (researchgate.net)

Cultural Competence In Health and Human Services | NPIN (cdc.gov)

<u>Cultural Competency – The Office of Minority Health (hhs.gov)</u>

Implicit Bias, Microaggressions, and Stereotypes Resources | NEA

Unconscious Bias Resources | diversity.ucsf.edu

Act, Communicating, Implicit Bias (racialequitytools.org)

https://kirwaninstitute.osu.edu/implicit-bias-training

https://www.uptodate.com/contents/racial-and-ethnic-disparities-in-obstetric-and-gynecologic-care-and-role-of-implicitbiases

https://www.contemporaryobgyn.net/view/overcoming-racism-and-unconscious-bias-in-ob-gyn

https://pubmed.ncbi.nlm.nih.gov/34016820/